JP2019517512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517512A5 JP2019517512A5 JP2018563110A JP2018563110A JP2019517512A5 JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5 JP 2018563110 A JP2018563110 A JP 2018563110A JP 2018563110 A JP2018563110 A JP 2018563110A JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- months
- ctla
- body weight
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 14
- 230000037396 body weight Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 101150061338 mmr gene Proteins 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims 1
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 229910015837 MSH2 Inorganic materials 0.000 claims 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims 1
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims 1
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000033607 mismatch repair Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155878A JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345662P | 2016-06-03 | 2016-06-03 | |
| US62/345,662 | 2016-06-03 | ||
| PCT/US2017/035822 WO2017210637A1 (en) | 2016-06-03 | 2017-06-02 | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Division JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517512A JP2019517512A (ja) | 2019-06-24 |
| JP2019517512A5 true JP2019517512A5 (enExample) | 2020-07-16 |
Family
ID=59078186
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563110A Pending JP2019517512A (ja) | 2016-06-03 | 2017-06-02 | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11332529B2 (enExample) |
| EP (2) | EP3464373B1 (enExample) |
| JP (3) | JP2019517512A (enExample) |
| KR (3) | KR102702675B1 (enExample) |
| CN (1) | CN109476754A (enExample) |
| ES (1) | ES2897964T3 (enExample) |
| WO (1) | WO2017210637A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| EP4098278A1 (en) | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| MY188749A (en) * | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| KR102702675B1 (ko) | 2016-06-03 | 2024-09-05 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| MX2020006171A (es) * | 2018-01-12 | 2020-09-03 | Bristol Myers Squibb Co | Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer. |
| US12398209B2 (en) * | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| WO2020033283A1 (en) * | 2018-08-09 | 2020-02-13 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc |
| JP7470105B2 (ja) * | 2018-09-13 | 2024-04-17 | メルク・シャープ・アンド・ドーム・エルエルシー | 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ |
| WO2020198672A1 (en) * | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| GB201912107D0 (en) * | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| CN110656179A (zh) * | 2019-10-29 | 2020-01-07 | 至本医疗科技（上海）有限公司 | 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质 |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| CN113995835A (zh) * | 2021-10-09 | 2022-02-01 | 山东新创生物科技有限公司 | 戈氏梭菌芽孢联合pd-1抗体的应用 |
| EP4612182A1 (en) * | 2022-10-31 | 2025-09-10 | Agenus Inc. | Methods of treating colorectal cancer using an anti-ctla4 antibody |
| JP2026506594A (ja) * | 2023-02-09 | 2026-02-25 | アンボーゲン セラピューティクス インコーポレイテッド | 大腸癌の治療のための医薬キット及びその使用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| EP1340819A1 (en) * | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2005021743A1 (ja) * | 2003-08-29 | 2005-03-10 | Tanaka, Noriaki | 核酸増幅用プライマー及びこれを用いた大腸癌の検査方法 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2012122444A1 (en) | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| FI20115709A0 (fi) | 2011-07-01 | 2011-07-01 | Helsingin Yliopisto | Menetelmä perinnöllisten syöpien diagnosointiin |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| HUE046249T2 (hu) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| AU2015210886A1 (en) * | 2014-01-29 | 2016-09-01 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| EP4098278A1 (en) * | 2014-11-13 | 2022-12-07 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016197067A1 (en) | 2015-06-05 | 2016-12-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Gm-csf/cd40l vaccine and checkpoint inhibitor combination therapy |
| KR102702675B1 (ko) | 2016-06-03 | 2024-09-05 | 브리스톨-마이어스 스큅 컴퍼니 | 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도 |
| CN110505882A (zh) * | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
-
2017
- 2017-06-02 KR KR1020237010151A patent/KR102702675B1/ko active Active
- 2017-06-02 ES ES17731359T patent/ES2897964T3/es active Active
- 2017-06-02 CN CN201780048328.2A patent/CN109476754A/zh active Pending
- 2017-06-02 EP EP17731359.0A patent/EP3464373B1/en not_active Revoked
- 2017-06-02 US US16/306,290 patent/US11332529B2/en active Active
- 2017-06-02 JP JP2018563110A patent/JP2019517512A/ja active Pending
- 2017-06-02 EP EP21197402.7A patent/EP3988570A1/en active Pending
- 2017-06-02 WO PCT/US2017/035822 patent/WO2017210637A1/en not_active Ceased
- 2017-06-02 KR KR1020247029228A patent/KR20240134249A/ko active Pending
- 2017-06-02 KR KR1020187038115A patent/KR102515509B1/ko active Active
-
2022
- 2022-04-19 US US17/724,399 patent/US20220356254A1/en not_active Abandoned
- 2022-09-29 JP JP2022155878A patent/JP7721494B2/ja active Active
-
2024
- 2024-07-29 US US18/787,822 patent/US20250026831A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093572A patent/JP2025143276A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108289892B (zh) | 治疗组合物、组合和使用方法 | |
| JP2018500332A5 (enExample) | ||
| JP2019503387A5 (enExample) | ||
| JP2014533279A5 (enExample) | ||
| JP2022050618A5 (enExample) | ||
| TWI890661B (zh) | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法 | |
| JP2018518454A5 (enExample) | ||
| ES2985352T3 (es) | Anticuerpos para radionúclidos quelados | |
| JP2018522887A5 (enExample) | ||
| JP2018516966A5 (enExample) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| JP2018516969A5 (enExample) | ||
| IL313952A (en) | Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment | |
| JP2019519499A5 (enExample) | ||
| JP2020508317A5 (enExample) | ||
| JP2021528423A5 (enExample) | ||
| JP2019515008A5 (enExample) | ||
| JP2020502271A5 (enExample) | ||
| JP2017501167A5 (enExample) | ||
| JP2016536314A5 (enExample) | ||
| JP2015534577A5 (enExample) | ||
| JP2019517511A5 (enExample) | ||
| JP2019517512A (ja) | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 | |
| JP2015534578A5 (enExample) | ||
| JP2017514795A5 (enExample) |